Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension

Biotechnology Journal

Volumn 9, Issue 9, 2014, Pages 1215-1222

  Malm, Magdalena ^a   Bass, Tarek ^a   Gudmundsdotter, Lindvi ^b   Lord, Martin ^a   Frejd, Fredrik Y ^b,c   Ståhl, Stefan ^a   Löfblom, John ^a  

^a ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^b Affibody AB   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Affibody molecules; Albumin binding domain; Bispecific; Half life extension; HER3

Indexed keywords

ANTIBODIES; PURIFICATION; TUMORS;

AFFIBODY MOLECULES; ALBUMIN-BINDING DOMAIN; BISPECIFIC; HALF-LIFE EXTENSION; HER3; AFFINITY PURIFICATION; BINDING DOMAIN; IN-VIVO;

MOLECULES;

ALBUMINOID; BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; LIGAND; PROTEIN BINDING;

AFFINITY CHROMATOGRAPHY; BIOENGINEERING; CELL PROLIFERATION; DRUG EFFECTS; GENETIC PROCEDURES; HALF LIFE TIME; HUMAN; IMMUNOLOGY; PHOSPHORYLATION; PROCEDURES; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ALBUMINS; ANTIBODIES, BISPECIFIC; BIOENGINEERING; BIOSENSING TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATOGRAPHY, AFFINITY; HALF-LIFE; HUMANS; LIGANDS; PHOSPHORYLATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 84906948848     PISSN: 18606768     EISSN: 18607314     Source Type: Journal    
DOI: 10.1002/biot.201400009     Document Type: Article

References (25)

1. Kontermann, R., Dual targeting strategies with bispecific antibodies. MAbs 2012, 4, 182-197.
2. Byrne, H., Conroy, P. J., Whisstock, J. C., O'Kennedy, R. J., A tale of two specificities: Bispecific antibodies for therapeutic and diagnostic applications. Trends Biotechnol. 2013, 31, 621-632.
3. Sergina, N. V., Rausch, M., Wang, D., Blair, J. et al., Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 2007, 445, 437-441.
4. Gijsen, M., King, P., Perera, T., Parker, P. J. et al., HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2010, 8, e1000563.
5. Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M. et al., The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl. Acad. Sci. USA 2003, 100, 8933-8938.
6. Baselga, J., Swain, S. M., Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9, 463-475.
7. Aurisicchio, L., Marra, E., Roscilli, G., Mancini, R., Ciliberto, G., The promise of anti-ErbB3 monoclonals as new cancer therapeutics. Oncotarget 2012, 3, 744-758.
8. Robinson, M. K., Hodge, K. M., Horak, E., Sundberg, A. L. et al., Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro. Br. J. Cancer 2008, 99, 1415-1425.
9. McDonagh, C. F., Huhalov, A., Harms, B. D., Adams, S. et al., Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol. Cancer Ther. 2012, 11, 582-593.
10. Lofblom, J., Frejd, F. Y., Stahl, S., Non-immunoglobulin based protein scaffolds. Curr. Opin. Biotechnol. 2011, 22, 843-848.
11. Lofblom, J., Feldwisch, J., Tolmachev, V., Carlsson, J. et al., Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett. 2010, 584, 2670-2680.
12. Orlova, A., Magnusson, M., Eriksson, T. L., Nilsson, M. et al., Tumor imaging using a picomolar affinity HER2 binding affibody molecule. Cancer Res. 2006, 66, 4339-4348.
13. Kronqvist, N., Malm, M., Gostring, L., Gunneriusson, E. et al., Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. Protein Eng. Des. Sel. 2011, 24, 385-396.
14. Lofblom, J., Bacterial display in combinatorial protein engineering. Biotechnol. J. 2011, 6, 1115-1129.
15. Lindberg, H., Johansson, A., Hard, T., Stahl, S., Lofblom, J., Staphylococcal display for combinatorial protein engineering of a head-to-tail affibody dimer binding the Alzheimer amyloid-beta peptide. Biotechnol. J. 2013, 8, 139-145.
16. Gostring, L., Malm, M., Hoiden-Guthenberg, I., Frejd, F. Y. et al., Cellular effects of HER3-specific affibody molecules. PLoS One 2012, 7, e40023.
17. Jonsson, A., Dogan, J., Herne, N., Abrahmsén, L., Nygren, P. Å., Engineering of a femtomolar affinity binding protein to human serum albumin. Protein Eng. Des. Sel. 2008, 21, 515-527.
18. Andersen, J. T., Pehrson, R., Tolmachev, V., Daba, M. B. et al., Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain. J. Biol. Chem. 2011, 286, 5234-5241.
19. Tolmachev, V., Orlova, A., Pehrson, R., Galli, J. et al., Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule. Cancer Res. 2007, 67, 2773-2782.
20. Orlova, A., Jonsson, A., Rosik, D., Lundqvist, H. et al., Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein. J. Nucl. Med. 2013, 54, 961-968.
21. Feldwisch, J., Tolmachev, V., Lendel, C., Herne, N. et al., Design of an optimized scaffold for affibody molecules. J. Mol. Biol. 2010, 398, 232-247.
22. Gunneriusson, E., Nord, K., Uhlen, M., Nygren, P., Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling. Protein Eng. 1999, 12, 873-878.
23. Tolmachev, V., Hofstrom, C., Malmberg, J., Ahlgren, S. et al., HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [(m)Tc(CO)](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation. Bioconjug. Chem. 2010, 21, 2013-2022.
24. Kronqvist, N., Malm, M., Rockberg, J., Hjelm, B. et al., Staphylococcal surface display in combinatorial protein engineering and epitope mapping of antibodies. Recent Pat. Biotechnol. 2010, 4, 171-182.
25. Malm, M., Kronqvist, N., Lindberg, H., Gudmundsdotter, L. et al., Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification. PLoS One 2013, 8, e62791.